Report

Recent developments in targeting access to high cost medicines in Australia

24 Nov 2005
Description

The Pharmaceutical Benefits Scheme has developed a set of arrangements to control access to high-cost medicines, including tumour necrosis factor-alpha inhibitors (TNFIs) for the treatment of rheumatoid arthritis. In this article Christine Y. Lu, Jan Ritchie, Kenneth M. Williams and Richard O. Day explore basic views on the restricted access to TNFIs in order to confirm where further investigation should take place in the next phase.

Publication Details
Published year only: 
2005
0
Share
Share
Geographic Coverage
Advertisement